Search Results - "HOFFMAN, John P"

Failure to Adhere to Protocol Specified Radiation Therapy Guidelines Was Associated With Decreased Survival in RTOG 9704—A Phase III Trial of Adjuvant Chemotherapy and Chemoradiotherapy for Patients With Resected Adenocarcinoma of the Pancreas by Abrams, Ross A., M.D, Winter, Kathryn A., M.S, Regine, William F., M.D, Safran, Howard, M.D, Hoffman, John P., M.D, Lustig, Robert, M.D, Konski, Andre A., M.D, Benson, Al B., M.D, Macdonald, John S., M.D, Rich, Tyvin A., M.D, Willett, Christopher G., M.D

“…Purpose In Radiation Therapy Oncology Group 9704, as previously published, patients with resected pancreatic adenocarcinoma received continuous infusion 5-FU…”
Get full text

Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704 by BERGER, Adam C, GARCIA, Miguel, HOFFMAN, John P, REGINE, William F, ABRAMS, Ross A, SAFRAN, Howard, KONSKI, Andre, BENSON, Alan B, MACDONALD, John, WILLETT, Christopher G

“…CA 19-9 is an important tumor marker in patients with pancreatic adenocarcinoma. A secondary end point of Radiation Therapy Oncology Group trial 9704 was…”
Get full text

An iPSC Line from Human Pancreatic Ductal Adenocarcinoma Undergoes Early to Invasive Stages of Pancreatic Cancer Progression by Kim, Jungsun, Hoffman, John P., Alpaugh, R. Katherine, Rhim, Andrew D., Reichert, Maximilian, Stanger, Ben Z., Furth, Emma E., Sepulveda, Antonia R., Yuan, Chao-Xing, Won, Kyoung-Jae, Donahue, Greg, Sands, Jessica, Gumbs, Andrew A., Zaret, Kenneth S.

“…Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis and lacks a human cell model of early disease progression. When human PDAC cells are…”
Get full text

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132 by Wang, Dian, Zhang, Qiang, Blanke, Charles D., Demetri, George D., Heinrich, Michael C., Watson, James C., Hoffman, John P., Okuno, Scott, Kane, John M., von Mehren, Margaret, Eisenberg, Burton L.

“…Background Imatinib inhibits the KIT and PDGFR tyrosine kinases, resulting in its notable antitumor activity in gastrointestinal stromal tumor (GIST). We…”
Get full text

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 by Eisenberg, Burton L., Harris, Jonathan, Blanke, Charles D., Demetri, George D., Heinrich, Michael C., Watson, James C., Hoffman, John P., Okuno, Scott, Kane, John M., von Mehren, Margaret

“…Background Therapy for gastrointestinal stromal tumors (GIST) has changed significantly with the use of imatinib mesylate (IM). Despite the success of this…”
Get full text

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer by Beglyarova, Natalya, Banina, Eugenia, Zhou, Yan, Mukhamadeeva, Ramilia, Andrianov, Grigorii, Bobrov, Egor, Lysenko, Elena, Skobeleva, Natalya, Gabitova, Linara, Restifo, Diana, Pressman, Max, Serebriiskii, Ilya G, Hoffman, John P, Paz, Keren, Behrens, Diana, Khazak, Vladimir, Jablonski, Sandra A, Golemis, Erica A, Weiner, Louis M, Astsaturov, Igor

“…Even when diagnosed prior to metastasis, pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with almost 90% lethality, emphasizing the need…”
Get full text

The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival After Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704 by Showalter, Timothy N., M.D, Winter, Kathryn A., M.S, Berger, Adam C., M.D, Regine, William F., M.D, Abrams, Ross A., M.D, Safran, Howard, M.D, Hoffman, John P., M.D, Benson, Al B., M.D, MacDonald, John S., M.D, Willett, Christopher G., M.D

“…Purpose Lymph node status is an important predictor of survival in pancreatic cancer. We performed a secondary analysis of Radiation Therapy Oncology Group…”
Get full text

Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer by Chun, Yun Shin, Cooper, Harry S., Cohen, Steven J., Konski, Andre, Burtness, Barbara, Denlinger, Crystal S., Astsaturov, Igor, Hall, Michael J., Hoffman, John P.

“…Background Pathologic response to preoperative therapy is increasingly recognized as an important prognostic factor in solid tumors. The impact of pathologic…”
Get full text

Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma by Cohen, Steven J, Alpaugh, R Katherine, Palazzo, Irma, Meropol, Neal J, Rogatko, André, Xu, Zhiheng, Hoffman, John P, Weiner, Louis M, Cheng, Jonathan D

“…Given the extensive desmoplastic response associated with pancreatic adenocarcinoma, we hypothesized that the stromal protein fibroblast activation protein…”
Get full text

Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial by SMALL, William, BERLIN, Jordan, KINSELLA, Timothy J, MERCHANT, Nipun B, HOFFMAN, John P, BENSON, Al B, NICOL, Steven, XU, Rong M, GILL, John F, MCGINN, Cornelius J, FREEDMAN, Gary M, LAWRENCE, Theodore, TALAMONTI, Mark S, MULCAHY, Mary F, BAPSI CHAKRAVARTHY, A, KONSKI, Andre A, ZALUPSKI, Mark M, PHILIP, Philip A

“…Gemcitabine is effective in the treatment of pancreatic cancer and is a potent radiosensitizer. This study assessed safety and efficacy of full-dose…”
Get full text

Nonneoplastic celiac axis occlusion in patients undergoing pancreaticoduodenectomy by Farma, Jeffrey M., M.D, Hoffman, John P., M.D

“…Abstract Background Celiac artery occlusion occurs in a small percentage of the population. Identifying this is critical in planning for…”
Get full text

How to Define and Manage Borderline Resectable Pancreatic Cancer by Papavasiliou, Pavlos, MD, Chun, Yun Shin, MD, Hoffman, John P., MD

“…Historically, borderline resectable (BLR) pancreatic cancer has had many definitions, which has made interpretation of treatment data and outcomes difficult…”
Get full text

Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 ≤90 U/mL and Comparison to the CONKO-001 Trial by Berger, Adam C., MD, Winter, Kathryn, MS, Hoffman, John P., MD, Regine, William F., MD, Abrams, Ross A., MD, Safran, Howard, MD, Freedman, Gary M., MD, Benson, Alan B., MD, MacDonald, John, MD, Willett, Christopher G., MD

“…Purpose Radiation Therapy Oncology Group (RTOG) trial 9704 was the largest randomized trial to use adjuvant chemoradiation therapy for patients with pancreatic…”
Get full text

Potential prognostic biomarkers of pancreatic cancer by Chen, Kathryn T, Kim, Phillip D, Jones, Kelly A, Devarajan, Karthik, Patel, Bhavinkumar B, Hoffman, John P, Ehya, Hormoz, Huang, Min, Watson, James C, Tokar, Jeffrey L, Yeung, Anthony T

“…We evaluated whether pancreatic main duct fluid can provide protein biomarkers with prognostic value. Mass spectrometry proteomics was applied to as little as…”
Get full text

RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704 by Li, Donghui, PhD, Moughan, Jennifer, MS, Crane, Christopher, MD, Hoffman, John P., MD, Regine, William F., MD, Abrams, Ross A., MD, Safran, Howard, MD, Liu, Chang, MD, Chang, Ping, MD, Freedman, Gary M., MD, Winter, Kathryn A., MS, Guha, Chandan, MD, Abbruzzese, James L., MD

“…Purpose To confirm whether a previously observed association between RECQ1 A159C variant and clinical outcome of resectable pancreatic cancer patients treated…”
Get full text

The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma by Berger, Adam C, Watson, James C, Ross, Eric A, Hoffman, John P

“…Survival after curative resection for pancreatic adenocarcinoma remains poor; an important prognostic factor is lymph node (LN) status. Recent reports have…”
Get more information

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma by Brown, Kimberly M., M.D, Siripurapu, Veeriah, M.D, Davidson, Marson, M.D, Cohen, Steven J., M.D, Konski, Andre, M.D, Watson, James C., M.D, Li, Tiaynu, M.S, Ciocca, Vince, M.D, Cooper, Harry, M.D, Hoffman, John P., M.D

“…Abstract Background For patients with borderline resectable pancreatic cancer, preoperative chemoradiation and standalone chemotherapy may allow for R0…”
Get full text

Impact of preoperative therapy on patterns of recurrence in pancreatic cancer by Papavasiliou, Pavlos, Hoffman, John P, Cohen, Steven J, Meyer, Joshua E, Watson, James C, Chun, Yun Shin

“…Abstract Background A theoretical advantage of preoperative therapy in pancreatic adenocarcinoma is that it facilitates the early treatment of micrometastases…”
Get full text

Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence by Franco-Barraza, Janusz, Francescone, Ralph, Luong, Tiffany, Shah, Neelima, Madhani, Raj, Cukierman, Gil, Dulaimi, Essel, Devarajan, Karthik, Egleston, Brian L, Nicolas, Emmanuelle, Katherine Alpaugh, R, Malik, Ruchi, Uzzo, Robert G, Hoffman, John P, Golemis, Erica A, Cukierman, Edna

“…Desmoplasia, a fibrotic mass including cancer-associated fibroblasts (CAFs) and self-sustaining extracellular matrix (D-ECM), is a puzzling feature of…”
Get full text

Partial stomach-partitioning gastrojejunostomy and the success of this procedure in terms of palliation by Arrangoiz, Rodrigo, M.S., M.D, Papavasiliou, Pavlos, M.D, Singla, Smit, M.D., M.R.C.S. (Edinburgh), M.Sc, Siripurapu, Veeraiah, M.D, Li, Tianyu, M.S, Watson, James C., M.D, Hoffman, John P., M.D, Farma, Jeffrey M., M.D

“…Abstract Background In the 1990s, partial stomach-partitioning gastrojejunostomy (PSPG) was introduced. Benefits of this method are that it preferentially…”
Get full text